文献速递生殖医学

促黄体生成素可增强亚/低反应患者颗粒黄体细胞对促卵泡激素的体外反应

LH increases the response to FSH in granulosa-lutein cells from sub/poor-responder patients in vitro.
PubMed 文献 · Hum Reprod · 2023-01-01

该体外研究纳入286例接受辅助生殖技术取卵女性的颗粒黄体细胞,比较促卵泡激素(FSH)单用与联合0.5 nM促黄体生成素(LH)对环磷酸腺苷(cAMP)和孕酮生成的影响。结果显示正常反应者的细胞对FSH敏感性高于亚/低反应者,加用LH可提高所有组FSH效能,且亚/低反应者经FSH+LH处理后的反应与正常反应者单用FSH相似。

要点

  • 正常反应者颗粒黄体细胞对FSH的敏感性高于亚/低反应者。
  • 加用0.5 nM LH可提高所有组FSH诱导的cAMP和孕酮水平。
  • 亚/低反应者经FSH+LH处理后的体外反应与正常反应者单用FSH相似。

核心结论

  • FSH可诱导表型特异性的卵巢黄体细胞反应,加用LH可能弥补正常反应者与亚/低反应者之间cAMP和类固醇生成模式的差距。

研究设计与样本

  • 体外研究,收集2017年10月至2021年2月期间286例接受辅助生殖技术取卵的匿名女性的颗粒黄体细胞,盲法纯化、培养、基因分型后,用递增浓度FSH(nM)±0.5 nM LH处理,分别于3小时和24小时测定cAMP和孕酮水平,并根据供者卵巢反应回顾性分层为正常、亚和低反应组进行统计比较。

主要发现

  • 等摩尔FSH浓度下,正常反应者细胞诱导的cAMP水平约为亚/低反应者的2.5至4.2倍,孕酮平台水平约为1.2至2.1倍(ANOVA;P < 0.05)。
  • 在所有组中,加用LH均显著提高FSH诱导的cAMP和孕酮水平所反映的总体FSH效能(P > 0.05)。
  • 正常反应者单用FSH处理的体外终点与亚/低反应者经FSH+LH处理后的结果相似。
  • 组间未发现不同等位基因频率和FSH受体(FSHR)基因表达水平,排除了促性腺激素及其受体遗传学作为与正常、亚和低反应相关的因素。

临床怎么用

  • 作者认为该体外试验可能描述个体对促排卵方案的反应,以根据正常、亚和低反应状态实现辅助生殖技术刺激方案的个体化。
  • 作者认为该体外研究支持需要开展优化设计的随机临床试验,探索促黄体生成素在辅助生殖中的个体化使用。

局限性

  • 虽然对于体外研究而言实验重复数总体较高,但仍需要临床试验来证明本文评估的终点是否反映成功辅助生殖技术的参数。
  • 取卵后获取的颗粒黄体细胞可能不能完全再现窦卵泡阶段颗粒细胞对激素的反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does LH addition to FSH in vitro recover the human primary granulosa lutein cell (hGLC) sub/poor-response? SUMMARY ANSWER: A picomolar concentration of LH may recover the FSH-induced cAMP and progesterone production of hGLC from sub/poor-responder women. WHAT IS KNOWN ALREADY: Clinical studies suggested that FSH and LH co-treatment may be beneficial for the ovarian response of sub/poor-responders undergoing ovarian stimulation during ART. STUDY DESIGN, SIZE, DURATION: hGLC samples from 286 anonymous women undergoing oocyte retrieval for ART were collected from October 2017 to February 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: hGLCs from women undergoing ovarian stimulation during ART were blindly purified, cultured, genotyped and treated in vitro by increasing concentrations of FSH (nM) ±0.5 nM LH. cAMP and progesterone levels produced after 3 and 24 h, respectively, were measured. In vitro data were stratified a posteriori, according to the donors' ovarian response, into normo-, sub- and poor-responder groups and statistically compared. The effects of LH addition to FSH were compared with those obtained by FSH alone in all the groups as well. MAIN RESULTS AND THE ROLE OF CHANCE: hGLCs from normo-responders were shown to have higher sensitivity to FSH treatment than sub-/poor-responders in vitro. Equimolar FSH concentrations induced higher cAMP (about 2.5- to 4.2-fold), and progesterone plateau levels (1.2- to 2.1-fold), in cells from normo-responder women than those from sub-/poor-responders (ANOVA; P < 0.05). The addition of LH to the cell treatment significantly increased overall FSH efficacy, indicated by cAMP and progesterone levels, within all groups (P > 0.05). Interestingly, these in vitro endpoints, collected from the normo-responder group treated with FSH alone, were similar to those obtained in the sub-/poor-responder group under FSH + LH treatment. No different allele frequencies and FSH receptor (FSHR) gene expression levels between groups were found, excluding genetics of gonadotropin and their receptors as a factor linked to the normo-, sub- and poor-response. In conclusion, FSH elicits phenotype-specific ovarian lutein cell response. Most importantly, LH addition may fill the gap between cAMP and steroid production patterns between normo- and sub/poor-responders. LIMITATIONS, REASONS FOR CAUTION: Although the number of experimental replicates is overall high for an in vitro study, clinical trials are required to demonstrate if the endpoints evaluated herein reflect parameters of successful ART. hGLC retrieved after ovarian stimulation may not fully reproduce the response to hormones of granulosa cells from the antral follicular stage. WIDER IMPLICATIONS OF THE FINDINGS: This in vitro assay may describe the individual response to personalize ART stimulation protocol, according to the normo-, sub- and poor-responder status. Moreover, this in vitro study supports the need to conduct optimally designed, randomized clinical trials exploring the personalized use of LH in assisted reproduction. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by Merck KGaA. M.L. and C.C. are employees of Merck KGaA or of the affiliate Merck Serono SpA. Other authors have no competing interests to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Sperduti S, Paradiso E, Anzivino C, et al. LH increases the response to FSH in granulosa-lutein cells from sub/poor-responder patients in vitro. Hum Reprod. 2023. PMID: 36367827. doi:10.1093/humrep/deac246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。